This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:starting:safety_warnings [07.03.2017] – [The Marshall Protocol is a serious commitment] sallieq | home:starting:safety_warnings [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 31: | Line 31: | ||
* why higher than normal doses of olmesartan (Benicar) are required | * why higher than normal doses of olmesartan (Benicar) are required | ||
* why the use of antibiotics while taking olmesartan can provoke dangerous levels of immunopathology | * why the use of antibiotics while taking olmesartan can provoke dangerous levels of immunopathology | ||
- | * why the use of azithromycin is considered particularly dangerous | + | * why the use of telmisartan or azithromycin is considered particularly dangerous |
It has been the experience of the staff and volunteers of Autoimmunity Research Foundation that those patients who understand the rationale for the different components and instructions of the MP have the most success and best treatment outcomes. | It has been the experience of the staff and volunteers of Autoimmunity Research Foundation that those patients who understand the rationale for the different components and instructions of the MP have the most success and best treatment outcomes. | ||
- | ===== Patients' | + | ===== Patients' |
Some [[physician|physicians]] consent to treat a patient with the MP after a cursory examination of the various [[home: | Some [[physician|physicians]] consent to treat a patient with the MP after a cursory examination of the various [[home: | ||
The MP involves signs and symptoms of disease that may be unfamiliar to many clinical practitioners: | The MP involves signs and symptoms of disease that may be unfamiliar to many clinical practitioners: | ||
- | * Patients on the MP may see temporary increases in inflammatory markers and symptom severity due to [[home: | + | * Patients on the MP will see temporary increases in inflammatory markers and symptom severity due to [[home: |
* Patients on the MP may have levels of [[home: | * Patients on the MP may have levels of [[home: | ||
* Olmesartan (Benicar) should not be discontinued in an [[home: | * Olmesartan (Benicar) should not be discontinued in an [[home: | ||
Line 66: | Line 66: | ||
- | ===== Immunopathology | + | ===== Immunopathology |
< | < | ||
Line 84: | Line 84: | ||
{{tag> | {{tag> | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
* Updated wording, but still think it could be made even better with more work. --Joyful May'13 | * Updated wording, but still think it could be made even better with more work. --Joyful May'13 | ||
- | * added " | + | |
- | * altered 3rd line to ' | + | |
+ | </nodisp> |